A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy

Annals of Hematology

Volumn 84, Issue 4, 2005, Pages 227-231

  Fiegl, Michael ^a   Büchner, Thomas ^b   Hiddemann, Wolfgang ^a   Braess, Jan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Elderly; Etoposide; Idarubicin; Relapse

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; VEPESID K;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; APLASIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; ELDERLY CARE; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEPTICEMIA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RISK; SURVIVAL ANALYSIS;

EID: 15844363442     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0943-y     Document Type: Article

References (21)

1. Behringer B, Pitako JA, Kunzmann R, Schmoor C, Behringer D, Mertelsmann R, Lubbert M (2003) Prognosis of older patients with acute myeloid leukemia receiving either induction or non-curative treatment: A single-center retrospective study. Ann Hematol 82:381-389 1:STN:280:DC%2BD3szisFGntQ%3D%3D
2. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717 1:CAS:528:DyaK28XhtlGgsrg%3D
3. Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857-1864 1:STN:280:BiiD2Mbps1I%3D
4. Degos L, Castaigne S, Tilly H, Sigaux F, Daniel MT (1985) Treatment of leukemia with low-dose ara-C: A study of 160 cases. Semin Oncol 12 [Suppl]:196-199 1:STN:280:BiqB2cvntFY%3D
5. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 78:2520-2526 1:STN:280:By2A1Mbnt10%3D
6. Falkson G, Coccia-Portugal MA, Vorobiof DA, Terblanche AP, Dreyer R (1986) Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia. Am J Clin Oncol 9:311-314 1:STN:280:BimA38%2FgsV0%3D
7. Harousseau JL, Rigal-Huguet F, Hurteloup P, Guy H, Milpied N, Pris J (1989) Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent. Eur J Haematol 42:182-185 1:STN:280:BiaC3sjkt1c%3D
8. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T (1999) Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576 1:STN:280:DC%2BD3c%2FhvVaksQ%3D%3D
9. Jackson GH, Taylor PR, Iqbal A, Galloway MJ, Turner G, Haynes A, Hamilton PJ, Russell N, Proctor SJ (1997) The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: A report of toxicity and efficacy. Leukemia 11:1193-1196 10.1038/sj.leu.2400726
10. Keldsen N, Karle H, Hansen NE, Nissen NI (1990) Oral idarubicin in elderly patients with acute myeloid leukemia. Eur J Haematol 45:60 1:STN:280:By%2BA3snnsVQ%3D
11. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted randomized comparison. Leukemia 12:1049-1055 10.1038/ sj.leu.2401066
12. Kusnierz-Glaz CR, Normann D, Weinberg R, Fuchs R, Flasshove M, Hiddemann, van de Loo J, Buchner T (1993) Subcutaneous low dose arabinosyl-cytosine and oral idarubicin in high risk adult acute myelogenous leukemia. Hematol Oncol 11:73-80 1:STN:280:ByuD3M%2FnslY%3D
13. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268-1274 1:STN:280:BiaA287ls1Q%3D
14. Lowenthal RM, Chesterman CN, Griffiths JD, Manoharan A, Harris MG, Herrmann RP, Rooney KF, Rozenberg MC, Salem HH, Wolf MM (1987) Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. Cancer Treat Rep 71:1279-1281 1:STN:280:BieD1c%2FhsFE%3D
15. Malik ST, Tucker J, Rohatiner AZ, Brace W, Lister TA (1989) Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia. Hematol Oncol 7:423-427 1:STN:280:By%2BD3svntV0%3D
16. Pagano L, Sica S, Marra R, Voso MT, Storti S, Di Mario A, Leone G (1991) Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients. Haematologica 76:517-518
17. Ruutu T, Almqvist A, Hallman H, Honkanen T, Jarvenpaa E, Jarventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M, Nousiainen T, Pelliniemi TT, Rajamaki A, Remes K, Sarkkinen R, Sinisalo M, Timonen T, Volin L, Elonen E (1994) Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: A randomized comparison with 5-day TAD. Finnish Leukemia Group. Leukemia 8:11-15 1:STN:280:ByuC3MfltlA%3D
18. Tilly H, Castaigne S, Bordessoule D, Sigaux F, Daniel MT, Monconduit M, Degos L (1985) Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 55:1633-1636 1:STN:280:BiqC2M7lvVw%3D
19. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, Desablens B, Henry-Amar M, Degos L (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272-279 1:STN:280:By%2BC3s3otlA%3D
20. Webb DK (1999) Management of relapsed acute myeloid leukaemia. Br J Haematol 106:851-859 10.1046/j.1365-2141.1999.01629.x
21. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841-2851 1:CAS:528:DyaK28XmtlWjtrk%3D